Hao-Xiang Zhu

Hao-Xiang Zhu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2020 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
BZBeidi Zhu
Beidi Zhu
ZDZunguo Du
Zunguo Du
ZWZhengxin Wang
Zhengxin Wang
YLYang Li
Yang Li
JZJiming Zhang
Jiming Zhang
HZHao-Xiang Zhu
Hao-Xiang Zhu
Background. Congenital hepatic fibrosis is a hereditary fibropolycystic disease caused by ductal plate malformation. It is characterized by portal hypertension, but the manifestations, management, and outcome vary in children and adults. To raise awareness of medical staff, we have comprehensively compared the clinical features of congenital hepatic fibrosis between children and adults. Methods. We retrospectively enrolled all patients diagnosed with congenital hepatic fibrosis at the Huashan Hospital from August 2015 to August 2017 and analyzed their familial, clinical, laboratory, imaging, treatment, and follow-up data in detail. In addition, we reviewed cases with congenital hepatic fibrosis reported in the past 20 years in China and analyzed them according to the patients’ age. Results. A total of eight patients were diagnosed with congenital hepatic fibrosis in the study, including four children and four adults. The onset age of the children, who suffered from severe complications of portal hypertension and needed liver transplantation, ranged from 1 to 15 years old. The disorder developed in adults aged 26 to 60 years old. Three adults complained of recurrent abnormal liver function at the onset of illness, and they mainly received conservative treatments. The literature review included 30 children and 33 adults. In comparison, hepatomegaly was more common in children than in adults (57% vs. 21%, p=0.004). Malformation of kidneys and bile duct abnormalities were common, and multisystem involvement included eyes, other digestive organs, and genital and central nervous systems. Conclusions. Serious complications of portal hypertension developed in children requiring liver transplantation, while adults often had mild-to-moderate liver injuries upon onset. Adults with CHF varied a lot in clinical manifestations. Multiorgan involvement and unusual course are helpful to make a diagnosis. Timely histological assessment by liver biopsy and multidisciplinary cooperation are crucial for definitive diagnosis and early intervention.

24 February 2023 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
YGYifei Guo
Yifei Guo
JHJiajia Han
Jiajia Han
YZYongmei Zhang
Yongmei Zhang
CJChengmeng Jin
Chengmeng Jin
YZYao Zhang
Yao Zhang
JZJiming Zhang
Jiming Zhang
Background: Hepatitis B surface antigen (HBsAg) loss, namely, the functional cure, can be achieved through the pegylated interferon (PEG-IFN)-based therapy. However, it is an unignorable fact that a small proportion of patients who achieved functional cure develop HBsAg reversion (HRV) and the related factors are not well described.Methods: A total of 112 patients who achieved PEG-IFN-induced HBsAg loss were recruited. HBV biomarkers and biochemical parameters were examined dynamically. HBV RNA levels were assessed in the cross-sectional analysis. The primary endpoint was HRV, defined as the reappearance of HBsAg after PEG-IFN discontinuation.Results: HRV occurred in 17 patients during the follow-up period. Univariable analysis indicated that hepatitis B e antigen (HBeAg) status, different levels of hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) at the end of PEG-IFN treatment (EOT) were significantly associated with the incidence of HRV through using the log-rank test. Additionally, time-dependent receiver operating characteristic (ROC) analysis showed that the anti-HBs was superior to anti-HBc in predictive power for the incidence of HRV during the follow-up period. Multivariable Cox proportional hazard analysis found that anti-HBs ≥1.3 log10IU/L (hazard ratio (HR), 0.148; 95% confidence interval (CI), 0.044-0.502) and HBeAg negativity (HR, 0.183; 95% CI, 0.052-0.639) at EOT were independently associated with lower incidence of HRV. Cross-sectional analysis indicated that the HBV RNA levels were significantly correlated with the HBsAg levels in patients with HRV (r=0.86, p=0.003).Conclusions: EOT HBeAg negativity and anti-HBs ≥1.3 log10IU/L identify the low risk of HRV after PEG-IFN discontinuation.

18 October 2023 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
YGYue Guo
Yue Guo
YGYifei Guo
Yifei Guo
HYHuajian Ying
Huajian Ying
WYWeien Yu
Weien Yu
CSChen Shiqi
Chen Shiqi
JZJiming Zhang
Jiming Zhang
Introduction: The SARS-CoV-2 Omicron variant has decreased virulence and pathogenicity, yet the number of Omicron infections worldwide is unprecedentedly high, with rather high mortality and severe disease rate. Chronic kidney disease (CKD) patients are particularly vulnerable to the SARS-CoV-2 Omicron variant and have unique clinical outcomes. Methods: We retrospectively collected data from 2140 hospitalized patients with SARS-CoV-2 Omicron variant infection from March 29, 2022, to May 17, 2022. Demographic characteristics, ancillary examination results, and clinical treatments were described. Occurrence of critical COVID-19 or death and time of positive-to-negative conversion was defined as primary outcomes. The presence of COVID-19 pneumonia and the usage of respiratory or circulatory support was defined as secondary outcomes. Univariate or multivariate logistic regression analyses were performed to identify risk factors for primary outcomes. Results: 15.74% of CKD patients infected with the SARS-CoV-2 Omicron variant ended up with critical COVID-19 or death. Pre-existing CKD was a risk factor for critical COVID-19 or death and prolonged time of positive-to-negative conversion of SARS-CoV-2. Nirmatrelvir-ritonavir facilitated viral clearance among COVID-19 patients with non-severe CKD. Conclusion: We found patients with CKD and COVID-19 due to Omicron experienced worse clinical outcomes and prolonged time of positive-to-negative conversion of SARS-CoV-2 compared to patients without CKD, which helps rationalize limited medical resources and offers guidance for appropriate clinical treatments.

7 December 2022 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
JZJiming Zhang
Jiming Zhang
HZHao-Xiang Zhu
Hao-Xiang Zhu
YGYifei Guo
Yifei Guo
ZMZhenxuan Ma
Zhenxuan Ma
XQXun Qi
Xun Qi
JZJiming Zhang
Jiming Zhang
Background. Nucleotide analogues (NTs) monotherapy may have a more significant effect on reducing hepatitis B surface antigen (HBsAg) than nucleoside analogues (NSs) due to their immunomodulatory function. However, this superiority remains unknown when combined with PEGylated interferon α (PegIFNα). Therefore, this study aimed to explore whether NTs have more significant antiviral effects than NSs in combination therapy with PegIFNα. Methods. Chronic hepatitis B (CHB) patients treated with PegIFNα plus nucleos(t)ide analogues (NAs) were retrospectively recruited. Efficacy and the predictors of hepatitis B surface antigen (HBsAg) reduction >1 log10 IU/mL after 48 weeks were analyzed. Results. A total of 95 patients were included and divided into the PegIFNα + NTs group and the PegIFNα + NSs group. Propensity score matching (PSM) was performed. The PegIFNα + NTs group had a greater reduction of HBsAg (−3.52 vs. −2.33 log10 IU/mL, ) and a higher proportion of patients with HBsAg reduction >1 log10 IU/mL (100.0% vs. 72.2%, ) even after PSM. However, HBsAg and hepatitis B e-antigen (HBeAg) loss rates, HBeAg seroconversion rates, degree of HBeAg and hepatitis B virus (HBV) DNA decline, HBV DNA undetectable rates, and alanine aminotransferase (ALT) normalization rates showed no significant differences. Subgroup analyses showed the difference in the reduction of HBsAg was particularly evident in HBeAg-positive and the “add-on” subgroups. PegIFNα plus NTs (OR = 36.667, 95% CI = 3.837–350.384) was an independent predictor for HBsAg reduction >1 log10 IU/mL after 48 weeks. Conclusion. This study suggests that PegIFNα plus NTs may lead to more HBsAg reduction, especially in HBeAg-positive and “add-on” patients.

11 April 2025 in Medicine
Verified
Journal Article
Open access
BRBing Mm Ruan
Bing Mm Ruan
HZHao-Xiang Zhu
Hao-Xiang Zhu
Rationale: Systemic AL amyloidosis is a complex, multi-system disease with diverse clinical manifestations. Early and definite diagnosis helps to improve the prognosis. Patient concerns: At the beginning stage of the disease, the patient only presented with liver enlargement and abnormal liver function. Diagnoses: Conventional echocardiography “ECG” amyloidosis screening spot tracking imaging, etc. Pathology is the gold standard for diagnosis. Interventions: Elimination of clonal plasma cells or B cells that produce abnormal light chains. For eligible patients, autologous stem cell transplantation is the first choice. Outcomes: Systemic AL amyloidosis is often misdiagnosed due to a lack of typical symptoms and imaging signs. Lessons: This case highlights the patients with atypical clinical manifestations of AL amyloidosis, and the diagnosis should be made early to improve the prognosis. If there are risks and difficulties in pathological diagnosis, the cumulative organs can be indirectly evaluated with 18F-florbetapir positron emission tomography-computed tomography. Subsequent indirect diagnosis through less invasive, more accessible abdominal or rectal tissue.

11 March 2026 in Probiotics and Antimicrobial Proteins
Verified
Journal Article
Closed access
PDF file
LJLong Jianfei
Long Jianfei
WLWang Li
Wang Li
XXXiang Xi
Xiang Xi
WLWei Lanyi
Wei Lanyi
HTHe Tianye
He Tianye
BWBin Wang
Bin Wang